A license agreement from UCB to Pheno Therapeutics will enable the acceleration of a promising new drug tackling neurological diseases towards clinical development.
VGXI, a subsidiary of GeneOne, signed a licensing agreement with Houston Methodist Research Institute to produce RNA one of the most valued clinical ingredients.
Ncardia has entered into a non-exclusive licensing agreement with Evotec through which the drug discovery solutions company will gain access to Ncardia’s stem cell derived cellular disease modeling IP.
Takeda has agreed to pay $100m (€85m) upfront for rights to make and sell to Tesaro Inc’s drug Zejula in Japan, South Korea, Taiwan, Russia and Australia.
Arecor has entered a £45m ($56m) agreement to develop once daily injection of Cadila Pharmaceuticals’ basal insulin product using its reformulation technology.
DSM Sinochem Pharmaceuticals has licensed enzyme-based antibiotic production IP to Sandoz and accused Sinopharm Weiqida Pharmaceutical of patent infringement.
Lonza has licensed rights to synthetic adeno-associated viral (AAV) vectors developed by scientists at US hearing research centre, Massachusetts Eye and Ear.
Sanofi is poised to terminate its Auvi-Q marketing deal says PDL Biopharma, citing manufacturing issues last year which led to a complete recall of the epinephrine injection product.
Swiss CMO Lonza and clinical-stage biopharma company arGEN-X have entered into a multi-product commercial license agreement for making arGEN-X’s therapeutic antibodies.
MonosolRx has found a new US licensee for its oral film ondansetron product, Zuplenz, signing up Galena BioPharma nearly four years after previous partner Strativa handed the drug back.
Enteris has secured its first partnership to develop metabolic peptides for Nordic Bioscience using an oral delivery platform it says offers unparalleled bioavailability.
Codexis has denied breaching its licensing deal with Dyadic International and says losing rights to the C1 fungal expression system would hit its CodeXyme business hard.
The Big Pharma company has licensed a range of compounds to molecule research tools company Abcam to be made available for sale to pre-clinical researchers.
Peptide-based therapeutics specialists Unigene will focus on high valuation drug development and drug delivery opportunities after cutting loose its Site Directed Bone Growth (SDBG) patent portfolio.
Respiratory formulations specialist Vectura has licensed two dry-formulation technologies to GSK, further strengthening its position in the $25bn (€19bn) asthma and COPD market.
Cevec has exclusively licensed its transient CAP-T cell expression technology to Pevion for the manufacture and commercialisation of a protein antigen to vaccinate against an infectious disease.
Winsunny Pharma has exclusively licensed NMT’s HGCP technology, which produces APIs in low micron and nano-sized range, to manufacture a hyperlipidemia-controlling drug in China.
Dr Reddy’s Laboratories is combining some of its products with Aegis Therapeutics’ Intravail drug delivery technology after the companies entered into a partnership.
Bio-Path Holdings has signed an exclusive licence to develop a liposomal tumour targeting technology that delivers antisense and FAK siRNA and cuts toxicity.
Canada’s Winpak has gained an exclusive license to use Reynolds Packaging’s manufacturing know-how in the production of packaging for the drug and healthcare industries.
Drug delivery specialist Eurand is to begin supplying its extended release formulation of cyclobenzaprine HCl to South Korea’s Daewoong Pharmaceuticals.
A Brazilian firm has signed a licensing deal to take advantage of a
biopharmaceutical manufacturing technology which will allow the
company to locally manufacture complex biopharmaceuticals destined
for the South American market.
Finnish company DelSitech has signed a license agreement with Bayer
Innovation, a subsidiary of the Germany's Bayer group, in a deal
that could lead to the creation of a new generation of wound care
products.
Partnerships in drug delivery need to fairly reflect the risk all
parties take but there must also be a champion to drive the project
forward, according to Pfizer's director of drug delivery.
pSivida has signed a licensing agreement with Beijing's Med-Pharm,
in a move that will facilitate distribution of BrachySil in China -
the world's fastest growing market for pharmaceuticals.
UK pharmaceutical company ML Laboratories has acquired Quadrant
Technologies, a company specialising in drug formulation and
stabilisation, for £46.7 million (€70m), boosting its capabilities
in the development of inhaled medicines,...
Chromos Molecular Systems won another customer for its cell line
engineering technology yesterday, when world number one drugmaker
Pfizer took out a license for its ACE system, reports Phil
Taylor.
Canada's Chromos Molecular Systems and AppTec Laboratory Services
have teamed up to provide the biopharmaceutical industry with a
broader range of cell line engineering and contract manufacturing
services.
Crucell and DSM have announced the expansion of its original
agreement, building on existing work achieved in the PER.C6 Protein
and Monoclonal Antibody Licensing Business.
Cambrex has signed an exclusive license agreement that allows
access to two novel, quantitative assay technologies for the
detection of contaminants such as pathogens in drugs.
Netherlands firm Pharming has acquired the patent portfolio of
former transgenic protein production specialist PPL Therapeutics,
at a stroke enhancing its proprietary position in this emerging
market.
Ireland's Elan Corp has signed up another heavyweight partner -
Janssen - for its NanoCrystals technology, designed to improve the
solubility of drug compounds.
